Publicacións nas que colabora con Esteban Daudén Tello (10)

2023

  1. Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1)

    Dermatology and Therapy, Vol. 13, Núm. 1, pp. 329-345

2021

  1. Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study

    European Journal of Clinical Nutrition, Vol. 75, Núm. 9, pp. 1368-1382

2019

  1. Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 3, pp. 355-364

2016

  1. Genome-Wide Pathway Analysis Identifies Genetic Pathways Associated with Psoriasis

    Journal of Investigative Dermatology, Vol. 136, Núm. 3, pp. 593-602

  2. Urine metabolome profiling of immune-mediated inflammatory diseases

    BMC Medicine, Vol. 14, Núm. 1

2015

  1. A deletion at adamts9-magi1 locus is associated with psoriatic arthritis risk

    Annals of the Rheumatic Diseases, Vol. 74, Núm. 10, pp. 1875-1881

  2. Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis

    Pharmacogenomics Journal, Vol. 15, Núm. 4, pp. 322-325

2014

  1. Directrices del grupo español de psoriasis (GEP) basadas en la evidencia para el uso de medicamentos biológicos en pacientes con psoriasis en localizaciones de difícil tratamiento (uñas, cuero cabelludo, palmas y plantas)

    Actas Dermo-Sifiliograficas

2012

  1. Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes

    Human Molecular Genetics, Vol. 21, Núm. 20, pp. 4549-4557

2011

  1. Clinical characteristics and disease course in patients treated with efalizumab following suspension of marketing authorization by the European Medicines Agency: A multicenter observational study

    Actas Dermo-Sifiliograficas, Vol. 102, Núm. 5, pp. 354-364